Provectus Biopharmaceuticals, Inc. (PVCT)
USD 0.13
(-0.76%)
USD 0.13
(-0.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.89 Million USD | 26.36% |
| 2022 | -3.36 Million USD | 26.88% |
| 2021 | -4.51 Million USD | 1.35% |
| 2020 | -4.64 Million USD | 14.13% |
| 2019 | -5.48 Million USD | 25.48% |
| 2018 | -7.34 Million USD | 44.68% |
| 2017 | -12.63 Million USD | 44.64% |
| 2016 | -23.82 Million USD | 0.86% |
| 2015 | -22.01 Million USD | -68.17% |
| 2014 | -9.56 Million USD | -718.42% |
| 2013 | -12.35 Million USD | 115.03% |
| 2012 | -15.42 Million USD | 32.24% |
| 2011 | -18.75 Million USD | -2.77% |
| 2010 | -15.73 Million USD | -90.17% |
| 2009 | -11.64 Million USD | -19.64% |
| 2008 | -9.58 Million USD | 1.24% |
| 2007 | -9.31 Million USD | -99.26% |
| 2006 | -4.94 Million USD | -7818.31% |
| 2005 | -786.94 Thousand USD | 96.12% |
| 2004 | -1.71 Million USD | 19.17% |
| 2003 | -1.99 Million USD | 71.22% |
| 2002 | -6.92 Million USD | -5229.45% |
| 2001 | -129.99 Thousand USD | -1030.48% |
| 2000 | -11.49 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -656.33 Thousand USD | -78.11% |
| 2024 Q1 | -268.36 Thousand USD | 26.13% |
| 2023 Q4 | -602.46 Thousand USD | 22.35% |
| 2023 Q2 | -782 Thousand USD | -0.26% |
| 2023 Q1 | -779.98 Thousand USD | -14.34% |
| 2023 FY | - USD | 13.72% |
| 2023 Q3 | -775.83 Thousand USD | 0.79% |
| 2022 Q1 | -997.46 Thousand USD | 18.2% |
| 2022 Q4 | -682.14 Thousand USD | -2.73% |
| 2022 Q3 | -664 Thousand USD | 35.96% |
| 2022 FY | - USD | 26.88% |
| 2022 Q2 | -1.03 Million USD | -3.96% |
| 2021 Q4 | -1.21 Million USD | -16.74% |
| 2021 Q2 | -1.18 Million USD | -0.57% |
| 2021 FY | - USD | 1.35% |
| 2021 Q3 | -1.04 Million USD | 11.71% |
| 2021 Q1 | -1.17 Million USD | 1.88% |
| 2020 Q1 | -1.24 Million USD | -18.95% |
| 2020 Q2 | -1.14 Million USD | 8.72% |
| 2020 Q4 | -1.19 Million USD | -9.23% |
| 2020 FY | - USD | 14.13% |
| 2020 Q3 | -1.09 Million USD | 3.77% |
| 2019 Q1 | -1.52 Million USD | 11.96% |
| 2019 Q2 | -1.63 Million USD | -7.27% |
| 2019 Q3 | -1.25 Million USD | 23.16% |
| 2019 Q4 | -1.05 Million USD | 16.22% |
| 2019 FY | - USD | 25.48% |
| 2018 Q2 | -2.94 Million USD | -7.49% |
| 2018 FY | - USD | 44.68% |
| 2018 Q4 | -1.72 Million USD | -45.62% |
| 2018 Q1 | -2.74 Million USD | 5.81% |
| 2018 Q3 | -1.18 Million USD | 59.73% |
| 2017 Q3 | -2.95 Million USD | 5.76% |
| 2017 Q4 | -2.9 Million USD | 1.55% |
| 2017 Q1 | -4.23 Million USD | 18.44% |
| 2017 FY | - USD | 44.64% |
| 2017 Q2 | -3.13 Million USD | 25.97% |
| 2016 Q2 | -4.87 Million USD | 41.53% |
| 2016 Q1 | -8.33 Million USD | 12.27% |
| 2016 Q3 | -5.5 Million USD | -12.98% |
| 2016 Q4 | -5.19 Million USD | 5.68% |
| 2016 FY | - USD | 0.86% |
| 2015 Q3 | -5.6 Million USD | -25.49% |
| 2015 Q1 | -4.54 Million USD | -286.21% |
| 2015 FY | - USD | -68.17% |
| 2015 Q2 | -4.46 Million USD | 1.7% |
| 2015 Q4 | -9.5 Million USD | -69.49% |
| 2014 FY | - USD | -718.42% |
| 2014 Q4 | -1.17 Million USD | 68.48% |
| 2014 Q1 | -4.21 Million USD | -138.02% |
| 2014 Q2 | -3.99 Million USD | 5.26% |
| 2014 Q3 | -3.73 Million USD | 6.44% |
| 2013 FY | - USD | 115.03% |
| 2013 Q4 | 11.07 Million USD | 529.68% |
| 2013 Q3 | -2.57 Million USD | 35.97% |
| 2013 Q2 | -4.02 Million USD | -86.97% |
| 2013 Q1 | -2.15 Million USD | 10.79% |
| 2012 Q2 | -4.56 Million USD | -21.07% |
| 2012 FY | - USD | 32.24% |
| 2012 Q1 | -3.77 Million USD | 27.07% |
| 2012 Q4 | -2.41 Million USD | 48.32% |
| 2012 Q3 | -4.67 Million USD | -2.27% |
| 2011 Q4 | -5.17 Million USD | 37.89% |
| 2011 Q1 | -3.21 Million USD | 52.98% |
| 2011 FY | - USD | -2.77% |
| 2011 Q2 | -6.05 Million USD | -88.38% |
| 2011 Q3 | -8.32 Million USD | -37.62% |
| 2010 FY | - USD | -90.17% |
| 2010 Q4 | -6.83 Million USD | 6.01% |
| 2010 Q3 | -7.27 Million USD | -35.84% |
| 2010 Q2 | -5.35 Million USD | -98.4% |
| 2010 Q1 | -2.69 Million USD | 8.36% |
| 2009 Q4 | -2.94 Million USD | -10.85% |
| 2009 FY | - USD | -19.64% |
| 2009 Q1 | -2.21 Million USD | 16.01% |
| 2009 Q2 | -3.83 Million USD | -73.24% |
| 2009 Q3 | -2.65 Million USD | 30.77% |
| 2008 Q3 | -2.25 Million USD | 11.99% |
| 2008 Q4 | -2.63 Million USD | -16.84% |
| 2008 FY | - USD | 1.24% |
| 2008 Q1 | -2.26 Million USD | 11.94% |
| 2008 Q2 | -2.56 Million USD | -13.16% |
| 2007 FY | - USD | -99.26% |
| 2007 Q1 | -2.32 Million USD | -39.65% |
| 2007 Q2 | -2.26 Million USD | 2.81% |
| 2007 Q3 | -2.69 Million USD | -18.95% |
| 2007 Q4 | -2.57 Million USD | 4.45% |
| 2006 Q4 | -1.66 Million USD | 6.61% |
| 2006 FY | - USD | -7818.31% |
| 2006 Q1 | -239.6 Thousand USD | -125.87% |
| 2006 Q2 | -1.25 Million USD | -423.52% |
| 2006 Q3 | -1.78 Million USD | -42.38% |
| 2005 Q3 | -120.47 Thousand USD | 64.3% |
| 2005 FY | - USD | 96.12% |
| 2005 Q4 | 926.32 Thousand USD | 868.89% |
| 2005 Q1 | -530.87 Thousand USD | 34.32% |
| 2005 Q2 | -337.45 Thousand USD | 36.43% |
| 2004 Q1 | -284.27 Thousand USD | 12.19% |
| 2004 FY | - USD | 19.17% |
| 2004 Q4 | -808.31 Thousand USD | 10.99% |
| 2004 Q3 | -908.07 Thousand USD | -628.43% |
| 2004 Q2 | 171.84 Thousand USD | 160.45% |
| 2003 Q1 | -568.24 Thousand USD | 91.86% |
| 2003 FY | - USD | 71.22% |
| 2003 Q3 | -665.78 Thousand USD | -19.8% |
| 2003 Q4 | -323.73 Thousand USD | 46.08% |
| 2003 Q2 | -446.2 Thousand USD | 11.8% |
| 2002 Q1 | -6594.00 USD | 94.34% |
| 2002 Q4 | -6.98 Million USD | -13251.82% |
| 2002 Q3 | -44 Thousand USD | -36.83% |
| 2002 Q2 | -38.21 Thousand USD | -479.6% |
| 2002 FY | - USD | -5229.45% |
| 2001 Q1 | -9999.00 USD | -149.99% |
| 2001 Q3 | -3400.00 USD | -340100.0% |
| 2001 Q2 | 1.00 USD | 100.01% |
| 2001 FY | - USD | -1030.48% |
| 2001 Q4 | -116.59 Thousand USD | -3329.24% |
| 2000 FY | - USD | 0.0% |
| 2000 Q2 | - USD | 100.0% |
| 2000 Q1 | -31.5 Thousand USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | 20 Thousand USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 95.928% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 51.217% |
| SQZ Biotechnologies Company | -64.14 Million USD | 95.491% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 83.349% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 103.076% |
| Mesoblast Limited | -62.38 Million USD | 95.364% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -88.296% |
| Genus plc | 73.7 Million USD | 103.924% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 56.253% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 18.457% |
| Marizyme, Inc. | -34.28 Million USD | 91.563% |
| ContraFect Corporation | -64.99 Million USD | 95.55% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 67.028% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 36.098% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -106.328% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -9.374% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -24.464% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -458.315% |
| Accustem Sciences Inc. | -3.74 Million USD | 22.798% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 94.003% |
| EV Biologics, Inc. | -1.26 Million USD | -128.258% |
| Q BioMed Inc. | -617.62 Thousand USD | -368.296% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 180.972% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -357.353% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -26.607% |
| Biomind Labs Inc. | -1.03 Million USD | -179.574% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 129.283% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 59.612% |
| Skye Bioscience, Inc. | -13.54 Million USD | 78.651% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -94.454% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -11469.304% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 25.538% |
| IMV Inc. | -35.52 Million USD | 91.858% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 81.775% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -15.602% |
| GB Sciences, Inc. | -1.41 Million USD | -103.701% |
| Alpha Cognition Inc. | -9.7 Million USD | 70.199% |
| HST Global, Inc. | -5303.00 USD | -54441.316% |
| CSL Limited | 4.78 Billion USD | 100.06% |
| Halberd Corporation | -74.27 Thousand USD | -3793.868% |
| Enzolytics Inc. | -2.12 Million USD | -36.3% |
| Resverlogix Corp. | -11.74 Million USD | 75.368% |
| Affymax, Inc. | -14.29 Million USD | 79.767% |
| SYBLEU INC | -141.57 Thousand USD | -1943.022% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 5.573% |
| argenx SE | -216.02 Million USD | 98.661% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 94.773% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 337.66% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -92.962% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 863.461% |
| AVAX Technologies, Inc. | -6.11 Million USD | 52.683% |
| Zenith Capital Corp. | -8.6 Million USD | 66.392% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.837% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -16502.526% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -18.225% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1543.14% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 92.703% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -176.431% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 43114.961% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -65.276% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -50.571% |
| BioStem Technologies, Inc. | -7.55 Million USD | 61.71% |
| ONE Bio Corp. | 13.61 Million USD | 121.247% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1497.194% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -40.609% |
| Agentix Corp. | -1.37 Million USD | -110.848% |
| LadRx Corporation | 412.28 Thousand USD | 801.539% |
| Cell Source, Inc. | -4.27 Million USD | 32.304% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -687.625% |
| Regen BioPharma, Inc. | 1.46 Million USD | 297.3% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -208.696% |
| NovAccess Global Inc. | -1.03 Million USD | -179.507% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 132.668% |
| Itoco Inc. | -1.86 Million USD | -54.753% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -661.9% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -159.169% |
| Kadimastem Ltd | -2.62 Million USD | -10.21% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1109.419% |
| CytoDyn Inc. | -18.02 Million USD | 83.957% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -3559.829% |
| Mobile Lads Corp. | -2.24 Million USD | -29.055% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -23551.37% |
| Qrons Inc. | -40.08 Thousand USD | -7116.202% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -495.523% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 648.378% |
| Rebus Holdings, Inc. | -951 Thousand USD | -204.135% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -172.345% |
| International Stem Cell Corporation | 202 Thousand USD | 1531.845% |
| Bioxytran, Inc. | -3.82 Million USD | 24.288% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5394.54% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -17.482% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 91.936% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -6327.391% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -5.636% |
| Neutra Corp. | -181.24 Thousand USD | -1495.792% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 85.652% |
| PureTech Health plc | -11.62 Million USD | 75.124% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 85.651% |
| IXICO plc | -707 Thousand USD | -309.098% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 62.364% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 94.017% |
| CSL Limited | 4.73 Billion USD | 100.061% |
| Cellectis S.A. | -92.63 Million USD | 96.878% |